If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Regulatory News (FUM)

Share Price Information for Futura Medical (FUM)

Share Price is delayed by 15 minutes
Get Live Data
0.56    0.05 (9.80%)
Bid:
0.471
Ask:
0.568
Spread: 0.097 (20.594%)
Market Cap: £3.26m
FUM Live PriceLast checked at - London Stock Exchange

Intraday Futura Medical Share Chart

Directorate Changes

20 Feb 2018 07:00

RNS Number : 3598F
Futura Medical PLC
20 February 2018
 

For immediate release

20 February 2018

 

 

 

 

 

Futura Medical plc

("Futura" or "the Company")

 

Directorate Changes

 

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, announces that Derek Martin, the Company's Finance Director, has resigned from the Board and will leave the Company with effect from the date of this announcement to pursue other business interests.

 

Angela Hildreth will join the Company in the role of Finance Director, Chief Operating Officer and Board Director with effect from the date of this announcement. Angela is an experienced executive with a track record gained in financial, operational and strategic roles in healthcare and other industries. Angela's experience includes the AIM market and development-stage companies.

 

Angela was most recently the UK finance director of Shield Therapeutics plc, having joined the business as its financial controller in 2011 when it was an unquoted start-up. Her breadth of roles at the business included finance, business development, human resources and IT.

 

James Barder, Futura's Chief Executive, said: "On behalf of the Board, I would like to thank Derek for his contribution to the development of the Company during almost 10 years as Finance Director having been appointed on 24 September 2008. We wish him all the best in his future activities.

 

"I am delighted to welcome Angela to the role of FD and COO at Futura. Her breadth of knowledge and commercial experience in the pharmaceutical sector will be of great value to the Company at a key stage in our development."

 

 

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Angela Hildreth (née Bowman), aged 38 years, has been a director of the following companies during the five years preceding the date of this announcement:

 

Current directorships Past directorships

Quaff Box Limited Shield Therapeutics Switzerland AG

Shield TX UK Limited

Phosphate Therapeutics Limited

 

There is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.

 

 

For any further information please contact:

 

 

Futura Medical plc

 

James Barder, Chief Executive

 

Tel: +44 (0)1483 685 670

mail to: james.barder@futuramedical.com

www.futuramedical.com

 

 

 

N+1 Singer (Nominated Adviser and Broker)

 

Aubrey Powell / Liz Yong

 

Tel:+44 (0) 20 7496 3000

 

 

For media enquiries please contact:

 

 

Buchanan

 

Mark Court / Sophie Wills / Stephanie Watson

Tel: +44 (0)20 7466 5000

 

 

 

Notes to Editors

 

Futura Medical plc

 

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

 

www.futuramedical.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAMMGZZVGFGRZG
Date   Source Headline
6th Mar 20177:00 amRNSResearch Confirms MED2002's US$1 Billion Potential
23rd Jan 20171:00 pmRNSNotice of Preliminary Results
18th Jan 20174:30 pmRNSDirector's dealings
13th Jan 20175:45 pmRNSDirector / PDMR Dealing and Grant of Options
12th Jan 20173:00 pmRNSDirector / PDMR Dealing and Total Voting Rights
11th Jan 201712:20 pmRNSDirector's Dealings
10th Jan 201712:40 pmRNSNED Remuneration and Total Voting Rights
10th Jan 20177:00 amRNSSigns UK Licensing Agreement in Pain Relief
5th Jan 20177:00 amRNSInitial Launch of CSD500 in MENA
28th Nov 20165:30 pmRNSCorrection: Notification of Major Interests
28th Nov 201612:00 pmRNSNotification of Major Interest in Shares
25th Nov 20165:25 pmRNSCorrection - Block Listing Update
25th Nov 20163:05 pmRNSBlock Listing Update
25th Nov 20169:30 amRNSNotification Of Major Interest In Shares
23rd Nov 20163:30 pmRNSNotification of Major Interest in Shares
16th Nov 20167:00 amRNSKen James to lead Futura's R&D
16th Nov 20167:00 amRNSMED2002 Update
15th Nov 20163:38 pmRNSResult of General Meeting
27th Oct 201612:45 pmRNSResult of Placing
27th Oct 20169:48 amRNSClose of Accelerated Bookbuild
27th Oct 20167:01 amRNSProposed Accelerated Bookbuild
27th Oct 20167:00 amRNSCSD500: Approval of TTK with Extended Shelf Life
13th Sep 20167:00 amRNSInterim Results
12th Sep 20165:45 pmRNSNotification of Major Interest in Shares
12th Sep 20163:00 pmRNSNotification of Major Interest in Shares
7th Sep 20167:00 amRNSMED2002: Breakthrough Results in $5 billion Market
25th Jul 20167:00 amRNSNotification of Half Year Results
21st Jun 20165:30 pmRNSResult of AGM
21st Jun 20167:00 amRNSAGM Statement
20th Jun 20167:00 amRNSLicenses CSD500 to Milsing for Southeast Europe
13th Jun 20167:00 amRNSManufacturing and Distribution Agreements with TTK
19th May 20164:30 pmRNSBlock Listing Update
4th May 20167:00 amRNSRecruitment Closes in MED2002 Study
26th Apr 201611:39 amRNSNotice of AGM
15th Mar 20167:00 amRNSPreliminary Results
7th Mar 20167:00 amRNSAppointment of Non-Executive Director
26th Feb 201612:00 pmRNSNotification of Major Interest in Shares
26th Jan 20167:00 amRNSCapital Markets Event
20th Jan 20167:00 amRNSCapital Markets Event
18th Jan 20162:33 pmRNSNotice of Preliminary Results
4th Jan 20161:15 pmRNSRemuneration of Non-Executive Directors
16th Dec 20157:00 amRNSExtends Shelf Life of CSD500
1st Dec 201510:13 amRNSNotification of Major Interest in Shares
24th Nov 20157:00 amRNSPositive Regulatory Update on Pain Portfolio
23rd Nov 20153:42 pmRNSBlocklisting Interim Review
23rd Nov 20153:18 pmRNSBlock Listing Update
17th Nov 20157:00 amRNSMED2002 Clinical Trial Update
23rd Oct 20157:00 amRNSNHS Reimbursement for MED2002 as a Special
14th Oct 20157:00 amRNSLicensing Agreement for MED2002
9th Oct 20157:30 amRNSNotification of Major Interest in Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.